NASDAQ · BDRX
Healthcare · Biotechnology
$0.80
Up+$0.05 (+6.21%)
Updated Sep 5, 2026, 12:45 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BDRX closed at $0.80 after 20 trading sessions, down 48.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $0.771 | $0.7988 | $0.7623 | $0.7984 | 99.61K |
| Sep 2, 2026 | $0.758 | $0.80 | $0.7553 | $0.7849 | 58.77K |
| Sep 1, 2026 | $0.79 | $0.81 | $0.7802 | $0.7808 | 82.69K |
| Aug 31, 2026 | $0.8576 | $0.8576 | $0.78 | $0.8117 | 114.31K |
| Aug 28, 2026 | $0.87 | $0.88 | $0.8303 | $0.8681 | 110.16K |
| Aug 27, 2026 | $0.96 | $0.96 | $0.8609 | $0.90 | 280.16K |
| Aug 26, 2026 | $1.07 | $1.08 | $0.93 | $0.9773 | 1.07M |
| Aug 25, 2026 | $1.455 | $1.51 | $1.15 | $1.18 | 16.61M |
| Aug 24, 2026 | $1.22 | $1.35 | $1.18 | $1.20 | 39.53K |
| Aug 21, 2026 | $1.28 | $1.32 | $1.215 | $1.27 | 56.09K |
| Aug 20, 2026 | $1.28 | $1.3499 | $1.1701 | $1.26 | 73.26K |
| Aug 19, 2026 | $1.36 | $1.5255 | $1.25 | $1.26 | 1.21M |
| Aug 18, 2026 | $1.43 | $1.5178 | $1.34 | $1.39 | 16.72K |
| Aug 17, 2026 | $1.53 | $1.61 | $1.40 | $1.42 | 32.71K |
| Aug 14, 2026 | $1.56 | $1.57 | $1.50 | $1.52 | 11.02K |
| Aug 13, 2026 | $1.52 | $1.57 | $1.45 | $1.56 | 42.56K |
| Aug 12, 2026 | $1.54 | $1.58 | $1.43 | $1.50 | 16.22K |
| Aug 11, 2026 | $1.55 | $1.60 | $1.51 | $1.58 | 24.03K |
| Aug 10, 2026 | $1.52 | $1.6495 | $1.48 | $1.60 | 24.13K |
| Aug 7, 2026 | $1.49 | $1.68 | $1.40 | $1.54 | 24.54K |
The latest Smart Investors Daily articles mentioning BDRX.
BDRX research
Company profile and research snapshot.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%
ChartMill · Aug 26, 2026
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Benzinga · Aug 26, 2026
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics (NASDAQ:SMMT) stock rose
Benzinga · Aug 25, 2026
Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increased
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDRX.
No results
No recent SID articles mention BDRX.
